Adavosertib (AZD1775): A Comprehensive Monograph on a First-in-Class WEE1 Kinase Inhibitor—From Proof-of-Concept to Clinical Discontinuation

Executive Summary

Adavosertib (AZD1775, MK-1775) is an investigational, orally bioavailable, first-in-class small molecule inhibitor of WEE1 kinase, a critical regulator of the G2/M cell cycle checkpoint. The development of adavosertib was predicated on a compelling scientific rationale centered on the principle of synthetic lethality. In cancer cells with a defective G1/S checkpoint, most commonly due to mutations in the TP53 tumor suppressor gene, the G2/M checkpoint becomes an indispensable mechanism for maintaining genomic integrity. By inhibiting WEE1, adavosertib abrogates this final checkpoint, forcing cells with unrepaired DNA damage into a premature and lethal mitosis, a process termed mitotic catastrophe. This mechanism offered the promise of a therapeutic window, selectively targeting cancer cells while sparing normal tissues with functional G1 checkpoint control.

Originated by Merck & Co. and extensively developed by AstraZeneca, adavosertib was evaluated in a broad and ambitious clinical program spanning numerous solid tumor types. The drug demonstrated consistent and reproducible signals of antitumor activity, both as a monotherapy and in combination with DNA-damaging agents like platinum chemotherapy and PARP inhibitors. The strongest evidence of efficacy emerged in gynecological malignancies, particularly uterine serous carcinoma and ovarian cancer, tumor types characterized by high rates of TP53 mutation and genomic instability. Furthermore, clinical investigation validated the relevance of other biomarkers of replication stress, such as CCNE1 amplification, which correlated with heightened sensitivity to WEE1 inhibition.

Despite these promising efficacy signals, the clinical development of adavosertib was persistently challenged by a difficult safety and tolerability profile. The on-target mechanism of action, while effective against cancer cells, also impacted rapidly proliferating normal tissues, leading to a high incidence of myelosuppression (neutropenia, anemia, thrombocytopenia) and gastrointestinal toxicities (diarrhea, nausea). This resulted in a narrow therapeutic window, where the doses required to achieve a meaningful clinical response frequently caused significant adverse events, necessitating dose interruptions, reductions, and treatment discontinuations. Ultimately, this unfavorable risk-benefit balance led AstraZeneca to discontinue the global development of adavosertib in 2022. Although adavosertib itself will not reach the market, its journey provided invaluable validation of WEE1 as a therapeutic target, illuminated key predictive biomarkers, and defined the central challenges that must be overcome by the next generation of WEE1 inhibitors.

1.0 Molecular Profile and Physicochemical Properties

This section provides a comprehensive summary of the chemical identity, nomenclature, and key physicochemical properties of adavosertib, establishing a foundational reference for the molecule.

1.1 Nomenclature and Identification

Adavosertib is an investigational small molecule that has been identified by several names and development codes throughout its history. Its development was initiated by Merck & Co. under the code MK-1775 and was later continued by AstraZeneca as AZD1775.[1] These codes, along with their variations (e.g., MK 1775, AZD-1775), are used extensively in scientific literature and clinical trial registries.[3] The non-proprietary generic name assigned to the compound is adavosertib.[1]

The molecule is systematically named according to IUPAC nomenclature as 1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-(prop-2-en-1-yl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one.[1] For precise identification and cross-referencing across scientific databases, it is assigned a unique set of identifiers, which are consolidated in Table 1.1.

1.2 Chemical Structure and Properties

Adavosertib is characterized by the molecular formula C27​H32​N8​O2​, corresponding to an average molecular weight of approximately 500.61 g/mol and a monoisotopic mass of 500.264822 Da.[1]

Chemically, it belongs to the class of organic compounds known as pyrazolopyrimidines and is further characterized by several functional substructures, including a phenylpiperazine moiety, a pyridine ring, and a tertiary alcohol group.[3] This complex heterocyclic structure is responsible for its specific interaction with the WEE1 kinase active site. In its purified form, adavosertib is described as a yellow solid powder.[4] Regarding its solubility, it is soluble in dimethyl sulfoxide (DMSO) at concentrations up to 70 mg/mL or 100 mM.[12]

For unambiguous representation in computational and cheminformatic applications, its structure is defined by standard identifiers such as the Canonical SMILES and the International Chemical Identifier (InChI) and its corresponding hash key (InChIKey), as detailed in Table 1.1.

Table 1.1: Chemical and Pharmacological Identifiers for Adavosertib
Identifier Type	Value
Generic Name	Adavosertib
Development Codes	AZD1775, MK-1775
DrugBank ID	DB11740 3
CAS Number	955365-80-7 1
PubChem CID	24856436 1
ChEMBL ID	CHEMBL1976040 13
IUPAC Name	1-[6-(2-hydroxypropan-2-yl)pyridin-2-yl]-6-[4-(4-methylpiperazin-1-yl)anilino]-2-(prop-2-en-1-yl)-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one 1
Molecular Formula	C27​H32​N8​O2​ 3
Average Molecular Weight	500.61 g/mol 13
Canonical SMILES	CC(C)(C1=NC(=CC=C1)N2C3=NC(=NC=C3C(=O)N2CC=C)NC4=CC=C(C=C4)N5CCN(CC5)C)O 10
InChIKey	BKWJAKQVGHWELA-UHFFFAOYSA-N 1

2.0 Pharmacodynamics: Targeting the G2/M Checkpoint Through WEE1 Inhibition

The therapeutic rationale for adavosertib is rooted in its highly specific mechanism of action as an inhibitor of WEE1 kinase, a pivotal regulator of the cell division cycle. This section details the function of WEE1, the molecular consequences of its inhibition by adavosertib, and the overarching principle of synthetic lethality that guided its clinical development.

2.1 The WEE1 Kinase: A Critical Cell Cycle Gatekeeper

WEE1 is a nuclear serine/threonine-protein kinase that functions as a critical gatekeeper of the cell cycle, primarily at the G2/M checkpoint, which precedes entry into mitosis.[7] Its primary role is to act as a negative regulator, preventing cells from prematurely initiating cell division, particularly in the presence of DNA damage.[18]

The molecular mechanism of WEE1 involves the inhibitory phosphorylation of cyclin-dependent kinases (CDKs), most notably CDK1 (also known as CDC2) and CDK2, at a specific tyrosine residue (Tyr15).[4] This phosphorylation event maintains the CDK1/Cyclin B complex in an inactive state.[5] Activation of this complex is the essential trigger for the G2-to-M phase transition. By inhibiting CDK1, WEE1 effectively enforces a cell cycle arrest, providing a crucial time window for the DNA damage response (DDR) network to repair any genomic lesions before the cell commits to segregation of its chromosomes during mitosis.[17] In addition to its role at the G2/M checkpoint, WEE1 also modulates CDK2 activity during the S-phase to regulate the firing of replication origins and prevent excessive replication stress.[16]

2.2 Adavosertib as a Potent and Selective WEE1 Inhibitor

Adavosertib is a first-in-class, potent, and selective ATP-competitive inhibitor of WEE1 kinase.[1] In cell-free biochemical assays, it demonstrates high potency, with a half-maximal inhibitory concentration (

IC50​) of 5.2 nM.[4]

By binding to and inhibiting WEE1, adavosertib prevents the inhibitory phosphorylation of CDK1 at Tyr15.[5] This leads to the premature and uncontrolled activation of the CDK1/Cyclin B complex, thereby overriding the G2/M checkpoint.[5] As a result, cells are forced to enter mitosis even if their DNA is damaged and unrepaired. This unscheduled mitotic entry with a compromised genome is a catastrophic event for the cell, leading to gross chromosomal abnormalities and ultimately triggering apoptotic cell death, a process known as mitotic catastrophe.[4] This direct engagement of the WEE1 target and subsequent decrease in phosphorylated CDK1 has been confirmed in pharmacodynamic analyses of tumor biopsies from patients treated in clinical trials.[26]

2.3 The Principle of Synthetic Lethality: Exploiting Cancer's Achilles' Heel

The central therapeutic hypothesis for adavosertib is based on the concept of synthetic lethality, which occurs when the simultaneous loss of two genes or pathways is lethal to a cell, whereas the loss of either one alone is not. The clinical development of adavosertib was designed to exploit a common vulnerability in many aggressive cancers: a defective G1/S checkpoint.[5]

A majority of human cancers, including over 90% of uterine serous carcinomas and approximately 80% of triple-negative breast cancers, harbor loss-of-function mutations in the tumor suppressor gene TP53.[12] The p53 protein is the master regulator of the G1/S checkpoint, which halts the cell cycle before DNA replication begins to allow for repair of DNA damage.[5] Cancer cells lacking functional p53 are unable to arrest at this G1 checkpoint and thus become critically dependent on the intra-S and G2/M checkpoints—both regulated by WEE1—to maintain genomic stability and survive.[5]

This differential dependency creates a therapeutic window. In a TP53-deficient cancer cell, inhibition of WEE1 by adavosertib effectively removes the last line of defense against genomic instability, leading to a synthetically lethal outcome.[5] In contrast, normal, healthy cells possess a functional p53-mediated G1 checkpoint. When exposed to a WEE1 inhibitor and any ambient DNA damage, these cells can arrest in G1, repair their DNA, and are therefore relatively spared from the lethal effects of premature mitotic entry.[5]

This hypothesis-driven approach directly informed the clinical development strategy for adavosertib. The drug was rationally tested in tumor types known for high rates of TP53 mutation, such as uterine serous carcinoma, ovarian cancer, and triple-negative breast cancer.[28] Furthermore, the ability of WEE1 inhibition to abrogate the DNA damage checkpoint provided a strong rationale for combining adavosertib with DNA-damaging agents, such as platinum-based chemotherapy (cisplatin, carboplatin), gemcitabine, and PARP inhibitors, with the goal of potentiating their cytotoxic effects.[15]

While TP53 mutation was the initial guiding principle, further research and clinical observation revealed that adavosertib's mechanism extends to a broader context of replication stress. WEE1 inhibition exacerbates replication stress by causing the unscheduled firing of replication origins during S-phase, a process that is particularly toxic to cells already experiencing high levels of endogenous replication stress.[16] This understanding led to the identification of other potential predictive biomarkers. For instance, preclinical studies demonstrated that cancer cells with amplification of the

CCNE1 gene, which encodes the cell cycle protein Cyclin E1 and is a potent driver of replication stress, are exquisitely sensitive to WEE1 inhibition.[33] This preclinical finding was translated directly into the clinic, with a Phase II trial (NCT03253679) specifically enrolling patients with

CCNE1-amplified tumors. In that trial, the subgroup of patients with epithelial ovarian cancer demonstrated a promising objective response rate of 36%.[34] This evolution in understanding—from a singular focus on

TP53 status to a broader appreciation of replication stress biomarkers like CCNE1—represents a key legacy of the adavosertib program and has heavily influenced the development strategy for next-generation WEE1 inhibitors.[37]

3.0 Pharmacokinetic Profile: Systemic Exposure and Disposition (ADME)

The pharmacokinetic (PK) profile of a drug, which describes its absorption, distribution, metabolism, and excretion (ADME), is fundamental to understanding its clinical behavior. For adavosertib, PK studies were crucial in defining dosing schedules, identifying potential drug interactions, and interpreting the variability in safety and efficacy observed across different patient populations.

3.1 Absorption

Adavosertib was developed as an orally administered agent.[10] Pharmacokinetic analyses from Phase I studies in patients with advanced solid tumors showed that the drug is absorbed at a moderate rate, with the time to reach maximum plasma concentration (

Tmax​) occurring approximately 3 to 4 hours after a single oral dose.[27]

A dedicated Phase I clinical trial (NCT03315091) was conducted to formally assess the effect of food on the absorption of adavosertib.[31] In this study, administration with a high-fat, high-calorie meal resulted in a slight decrease in the rate and extent of absorption. The maximum plasma concentration (

Cmax​) was reduced by 16%, and the total systemic exposure, as measured by the area under the plasma concentration-time curve (AUC), was reduced by 6% to 7%. The Tmax​ was delayed by approximately 2 hours in the fed state compared to the fasted state. Critically, the 90% confidence interval for the geometric mean ratio of AUC was contained within the standard bioequivalence limits of 0.80–1.25. This indicates that the effect of food on overall drug exposure is not considered clinically significant, allowing for the convenience of administering adavosertib without regard to meals.[27]

3.2 Distribution

Specific clinical data regarding the volume of distribution and tissue penetration of adavosertib in humans were not detailed in the available materials. However, as a small molecule, it is expected to distribute from the bloodstream into various tissues and organs.[41] Preclinical

in vivo studies in mouse xenograft models demonstrated that adavosertib could distribute into tumor tissues at concentrations sufficient to exert its pharmacological effect, though distribution into orthotopic brain tumors was found to be limited.[4]

3.3 Metabolism

In vitro studies have identified the primary metabolic pathway for adavosertib in humans as oxidation mediated by the Cytochrome P450 enzyme CYP3A4.[27] Minor contributions from flavin-containing monooxygenase 3 (FMO3) and 5 (FMO5) have also been suggested. The metabolism of adavosertib does not appear to produce any major circulating metabolites, with no single metabolite accounting for more than 10% of the parent drug concentration in plasma.[27]

The significant role of CYP3A4 in adavosertib's metabolism has important clinical implications for potential drug-drug interactions. Co-administration with strong inhibitors or inducers of CYP3A4 could alter adavosertib plasma concentrations, potentially leading to increased toxicity or reduced efficacy, respectively. Consequently, clinical trial protocols for adavosertib routinely prohibited the concomitant use of such agents.[43]

3.4 Excretion

Following a single oral dose, adavosertib exhibits a terminal elimination half-life (t1/2​) ranging from 9.0 to 12.3 hours.[27] This relatively short half-life was a key factor influencing the design of dosing schedules. Continuous daily dosing would likely lead to drug accumulation and increased toxicity, which drove the development of the complex, intermittent dosing regimens used in most clinical trials (e.g., dosing for several consecutive days followed by a drug-free period).[20] Specific details on the primary route of excretion (i.e., renal vs. fecal) were not available in the provided documentation.

3.5 Pharmacokinetic Variability

A critical finding from the adavosertib clinical program was the significant difference in drug exposure observed between Asian and Western patient populations. A dedicated Phase Ib study (NCT02341456) in Asian patients with advanced solid tumors revealed that systemic exposure (AUC) to adavosertib was 30–45% higher than that previously observed in Western patients administered the same dose.[16]

This pharmacokinetic difference had direct and severe clinical consequences. In the same study, the combination of adavosertib at 225 mg twice daily (bid) with paclitaxel and carboplatin—a dose established in Western patients—was deemed intolerable in the Asian population due to the occurrence of two dose-limiting toxicities: one case of grade 4 sepsis and one fatal (grade 5) case of acute respiratory distress syndrome.[16] This finding established a clear link between higher systemic drug exposure in this population and an increased risk of severe, life-threatening toxicity. As a result, the recommended Phase II dose (RP2D) for adavosertib in combination with chemotherapy for Asian patients was established at a lower level (175 mg bid) than for Western patients.[16] This underscores the critical importance of evaluating pharmacokinetics and safety in diverse ethnic populations during global drug development.

4.0 Clinical Development and Efficacy Across Malignancies

Adavosertib was investigated in one of the broadest clinical development programs for a targeted oncology agent, reflecting the widespread prevalence of its proposed biomarkers (TP53 mutation and genomic instability). The drug was evaluated as a monotherapy and in combination with various anticancer agents across a multitude of solid tumors. This section systematically reviews the efficacy results from pivotal clinical trials, organized by malignancy, to construct a comprehensive picture of its clinical activity. A summary of these key trials is presented in Table 4.1.

4.1 Gynecological Cancers: The Strongest Signal of Activity

The most compelling evidence for the clinical activity of adavosertib was consistently observed in gynecological malignancies, a finding that aligns strongly with the drug's mechanism of action.

4.1.1 Uterine Serous Carcinoma (USC)

USC, an aggressive subtype of endometrial cancer, represented a prime target for adavosertib, given that over 90% of these tumors harbor TP53 mutations.[28] A single-arm, two-stage Phase II study (NCT03668340) provided the initial strong proof-of-concept for adavosertib monotherapy in this population. In 34 evaluable women with recurrent USC, the trial demonstrated an impressive objective response rate (ORR) of 29.4%, with a 6-month progression-free survival (PFS6) rate of 47.1%. The responses were notably durable, with a median PFS of 6.1 months and a median duration of response (DoR) of 9.0 months.[46]

These encouraging results led to the larger, multicenter, single-arm Phase IIb ADAGIO study (NCT04590248), which enrolled 109 treated patients. The ADAGIO trial confirmed the signal of antitumor activity, reporting an ORR of 26.0% by blinded independent central review. However, the durability of response was less pronounced in this larger, more heavily pretreated population, with a median DoR of 4.7 months and a median PFS of only 2.8 months. The trial was ultimately challenged by significant toxicity issues, which complicated the interpretation of the efficacy results and highlighted the drug's narrow therapeutic window in this setting.[33]

4.1.2 Ovarian Cancer

Ovarian cancer, another malignancy characterized by high rates of TP53 mutation and genomic instability, was a major focus of the adavosertib development program. Several trials investigated adavosertib in combination with standard-of-care chemotherapy. A Phase II study (NCT01357161) evaluated the addition of adavosertib to paclitaxel and carboplatin in patients with platinum-sensitive, TP53-mutated ovarian cancer and showed a positive trend toward improved outcomes.[30] Another Phase II study (NCT01164995) demonstrated antitumor activity when adavosertib was combined with carboplatin in women with

TP53-mutated ovarian cancer that was refractory or resistant to first-line platinum-based therapy.[16]

A particularly important investigation was the Phase II EFFORT study (NCT03579316), which evaluated adavosertib in women with recurrent ovarian cancer that had become resistant to PARP inhibitors—a population with a significant unmet need. The study compared adavosertib monotherapy to a combination with the PARP inhibitor olaparib. Adavosertib monotherapy yielded a meaningful ORR of 23%, while the combination arm achieved an ORR of 29%. The clinical benefit rate (CBR), defined as the percentage of patients achieving a response or stable disease, was high in both arms (63% and 89%, respectively), with a median PFS of 5.5 months for monotherapy and 6.8 months for the combination. These results demonstrated that WEE1 inhibition could induce responses in a highly resistant setting, irrespective of BRCA mutation status.[53]

Further evidence of activity in ovarian cancer came from a biomarker-driven Phase II trial (NCT03253679) that enrolled patients with advanced refractory solid tumors harboring CCNE1 amplification. Among the 14 patients with epithelial ovarian cancer in this trial, adavosertib monotherapy produced a strong efficacy signal, with an ORR of 36% and a PFS6 rate of 57%, further validating replication stress as a key determinant of sensitivity to WEE1 inhibition.[34]

4.2 Gastrointestinal Cancers

Adavosertib was also evaluated in gastrointestinal cancers, where TP53 and KRAS mutations are common drivers of tumorigenesis.

4.2.1 Metastatic Colorectal Cancer (mCRC)

The randomized Phase II FOCUS4-C trial (NCT01913459) was a landmark study that tested adavosertib monotherapy in a prospectively selected biomarker-defined population: patients with mCRC harboring both RAS and TP53 mutations who had achieved disease control after 16 weeks of induction chemotherapy. The trial met its primary endpoint, showing that adavosertib significantly improved PFS compared to active monitoring (median PFS 3.61 months vs. 1.87 months; Hazard Ratio = 0.35; p=0.0022). However, this PFS benefit did not translate into an improvement in overall survival (OS).[20] A critical finding from a prespecified subgroup analysis was a significant interaction with the location of the primary tumor. The clinical benefit of adavosertib was confined to patients with left-sided tumors (PFS HR = 0.24), whereas no benefit was observed in those with right-sided tumors (PFS HR = 1.02).[20]

4.2.2 Pancreatic Cancer

Given its high frequency of TP53 and KRAS mutations, pancreatic cancer was another rational target for adavosertib. Preclinical studies had demonstrated a synergistic effect between adavosertib and gemcitabine in p53-deficient pancreatic cancer xenografts.[9] This was translated into a Phase I dose-escalation trial (NCT02037230) that evaluated adavosertib in combination with gemcitabine and radiation for patients with newly diagnosed, locally advanced pancreatic cancer. The combination regimen was found to be well-tolerated and yielded a highly promising median OS of 21.7 months, which was substantially longer than historical outcomes for patients treated with gemcitabine and radiation alone, warranting further investigation.[1]

4.3 Other Advanced Solid Tumors

The clinical investigation of adavosertib extended to several other difficult-to-treat solid tumors.

• Triple-Negative Breast Cancer (TNBC): A Phase II study (NCT02617333) combined adavosertib with cisplatin for the first- or second-line treatment of metastatic TNBC. The trial reported an ORR of 26% but narrowly missed its prespecified primary endpoint, which required an ORR of >30% to be considered worthy of further study.[29]
• Small-Cell Lung Cancer (SCLC): Based on strong preclinical data showing synergy between WEE1 and PARP inhibition, a Phase Ib trial investigated the combination of adavosertib and olaparib in patients with refractory solid tumors, including a dose-expansion cohort for SCLC. However, the clinical activity in this setting was limited, with an ORR of only 11.1% and a median PFS of 1.5 months.[23]
• SETD2-Altered Tumors: A Phase II trial (NCT03284385) was designed based on a preclinical synthetic lethal hypothesis between SETD2 deficiency and WEE1 inhibition. This trial failed to demonstrate any objective responses in patients with SETD2-altered solid tumors, although a subset of patients experienced prolonged stable disease. This represented a case where a compelling preclinical rationale did not successfully translate into clinical efficacy.[45]

Table 4.1: Summary of Pivotal Adavosertib Clinical Trials
Trial ID / Name	NCT Number	Phase	Cancer Type	Patient Population / Biomarker	Intervention(s)	Key Efficacy Outcomes
ADAGIO	NCT04590248	IIb	Uterine Serous Carcinoma (USC)	Recurrent/persistent USC	Adavosertib Monotherapy	ORR: 26.0%; Median PFS: 2.8 months; Median DoR: 4.7 months 33
-	NCT03668340	II	Uterine Serous Carcinoma (USC)	Recurrent USC	Adavosertib Monotherapy	ORR: 29.4%; Median PFS: 6.1 months; PFS6: 47.1%; Median DoR: 9.0 months 46
EFFORT	NCT03579316	II	Ovarian Cancer	PARP inhibitor-resistant	Adavosertib Monotherapy vs. Adavosertib + Olaparib	ORR: 23% (mono) vs. 29% (combo); Median PFS: 5.5 months (mono) vs. 6.8 months (combo) 53
-	NCT03253679	II	Solid Tumors	CCNE1 amplification	Adavosertib Monotherapy	ORR (Ovarian Cancer subset): 36%; PFS6 (Ovarian Cancer subset): 57% 34
FOCUS4-C	NCT01913459	II	Metastatic Colorectal Cancer (mCRC)	RAS and TP53 mutant	Adavosertib Monotherapy vs. Active Monitoring	Median PFS: 3.61 vs. 1.87 months (HR=0.35); No OS benefit 20
-	NCT02037230	I	Pancreatic Cancer	Locally advanced	Adavosertib + Gemcitabine + Radiation	Median OS: 21.7 months 26
-	NCT02617333	II	Triple-Negative Breast Cancer (TNBC)	Metastatic, 0-1 prior lines	Adavosertib + Cisplatin	ORR: 26% (missed primary endpoint of >30%) 29

5.0 Safety, Tolerability, and Risk Profile

While adavosertib demonstrated clear signals of clinical efficacy, its development was ultimately curtailed by a challenging safety and tolerability profile. The on-target effects of inhibiting a fundamental cell cycle regulator in rapidly dividing normal tissues created a narrow therapeutic window. This section synthesizes the adverse event data from across the clinical program to provide a comprehensive overview of the drug's toxicity.

5.1 Overview of the Safety Profile

Across numerous Phase I and II clinical trials, both as a monotherapy and in combination with other agents, adavosertib was associated with a high incidence of treatment-related adverse events (TRAEs). In the Phase IIb ADAGIO trial, for instance, 97.2% of patients experienced a TRAE.[50] While many of these events were low-grade and considered manageable with supportive care and dose modifications, the frequency and severity of toxicities posed a significant clinical challenge.[21]

5.2 Common Treatment-Related Adverse Events

The pattern of common TRAEs was remarkably consistent across studies, pointing to class-specific, on-target effects of WEE1 inhibition in tissues with high cell turnover.

• Gastrointestinal (GI) Toxicity: Diarrhea and nausea were consistently reported as the most frequent TRAEs. Incidence rates for diarrhea ranged from approximately 56% to 85%, and for nausea, from 42% to 62% in key trials.[16] Vomiting and decreased appetite were also common, affecting 19-33% and 12-23% of patients, respectively.[16]
• Hematologic Toxicity: Myelosuppression was the most significant and often dose-limiting toxicity. Anemia, neutropenia (or decreased neutrophil count), and thrombocytopenia (or decreased platelet count) were observed at high frequencies across nearly all studies.[16]
• Constitutional Symptoms: Fatigue was a pervasive and impactful side effect, with reported rates of any-grade fatigue ranging from 36% to over 76% in various patient populations.[28]

5.3 Severe (Grade ≥3) and Dose-Limiting Toxicities

The rate of severe (Grade 3 or higher) TRAEs was substantial and represented the primary obstacle to sustained treatment delivery. In a Phase Ib monotherapy study, Grade ≥3 TRAEs were reported in 32.5% of patients [58], while in the ADAGIO trial in a more heavily pretreated USC population, this rate exceeded 60%.[33]

The most common severe adverse events were hematologic in nature, consistent with the on-target effects on bone marrow progenitor cells. Grade ≥3 neutropenia was reported in 21-32% of patients, and Grade ≥3 anemia occurred in 8-24% of patients in key studies.[16] Febrile neutropenia, a serious complication of neutropenia, was also reported.[16] Non-hematologic Grade ≥3 events included fatigue (up to 24%) and diarrhea (up to 9%).[20]

Critically, the toxicity profile included life-threatening events. In the Phase Ib study in Asian patients, dose-limiting toxicities included grade 4 sepsis and a grade 5 (fatal) case of acute respiratory distress syndrome.[16] The ADAGIO study reported one death from neutropenic sepsis that was considered possibly related to treatment.[50] These severe outcomes underscored the narrow margin between effective and unacceptably toxic doses.

5.4 Impact on Treatment Delivery

The cumulative burden of toxicity had a direct and significant impact on the ability of patients to remain on treatment. High rates of dose interruptions (ranging from 22.5% to 76.1%), dose reductions (11.3% to 60.6%), and permanent treatment discontinuations due to adverse events (14.7% to 17.4%) were consistently reported across multiple major trials.[21] This frequent need for dose modification indicates that many patients could not tolerate the protocol-specified starting dose, making it difficult to maintain the drug concentrations required for optimal efficacy. This dynamic—where the dose needed for a response is poorly tolerated—is the hallmark of a narrow therapeutic window and was the central challenge that ultimately proved insurmountable for the adavosertib program.

Table 5.1: Common Treatment-Related Adverse Events (Any Grade and Grade ≥3) Reported in Key Adavosertib Clinical Trials
Adverse Event	ADAGIO (USC, N=109) 50		Phase II (USC, N=34) 48		Phase Ib (Solid Tumors, N=80) 58
	Any Grade (%)	Grade ≥3 (%)	Any Grade (%)	Any Grade (%)	Grade ≥3 (%)
Diarrhea	59.6	8.3	76.5	56.3	9
Nausea	59.6	1.8	61.8	42.5	5
Anemia	58.7	8.3	-	-	-
Fatigue	39.4	13.8	64.7	36.3	-
Neutropenia	-	21.1	-	-	7
Thrombocytopenia	-	8.3	-	-	-

Note: Data reporting varies between studies; dashes indicate data not specified in the provided sources in this format.

6.0 Development Trajectory and Discontinuation

The strategic history of adavosertib, from its acquisition to its extensive clinical evaluation and eventual discontinuation, provides critical context for the scientific and clinical data. This trajectory illustrates the complex decision-making process in modern oncology drug development, where promising efficacy must be balanced against safety, tolerability, and the competitive landscape.

6.1 Development History

Adavosertib was originally discovered and developed by Merck & Co. under the code MK-1775. In 2013, AstraZeneca acquired the exclusive worldwide rights to the compound for an upfront payment of $50 million.[2] Under AstraZeneca's stewardship as AZD1775, adavosertib became a cornerstone of the company's DNA Damage Response (DDR) portfolio, a strategic area of focus built on the concept of synthetic lethality.[1] For nearly a decade, AstraZeneca sponsored a vast and comprehensive clinical development program to evaluate the drug's potential across a wide array of cancers.

6.2 Regulatory Status

Throughout its development, adavosertib remained an investigational agent and did not receive marketing approval from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or other major regulatory bodies.[59]

However, it did achieve certain regulatory milestones that acknowledged its potential in specific areas of unmet need:

• Orphan Drug Designation: Adavosertib was granted Orphan Drug Designation for the treatment of ovarian cancer by a regulatory authority, a status intended to encourage the development of drugs for rare diseases.[64]
• EMA Pediatric Waiver: On December 3, 2021, the EMA's Paediatric Committee (PDCO) granted a product-specific waiver for adavosertib in all pediatric populations for the treatment of malignant endometrial neoplasms and pancreatic cancer. This decision was based on the grounds that these diseases occur only in adult populations, thereby waiving the requirement for a Paediatric Investigation Plan (PIP) for these indications.[10]

6.3 Discontinuation of Development

In a strategic pipeline update in July 2022, AstraZeneca officially announced the discontinuation of the adavosertib development program. The drug was removed from its Phase II pipeline, halting further investigation for ovarian cancer, uterine serous cancer, and other solid tumors.[2]

The primary driver for this decision was the cumulative evidence from the clinical trial program pointing to an unfavorable risk-benefit profile due to the drug's challenging tolerability.[37] While trials like FOCUS4-C in colorectal cancer and the early USC study produced statistically significant or highly encouraging efficacy results, the magnitude of this benefit was often modest and came at the cost of significant toxicity.[20] The later ADAGIO trial in USC further solidified this concern, where an efficacy signal was confirmed but was overshadowed by high rates of severe adverse events, dose modifications, and treatment discontinuations.[51]

This pattern demonstrated a consistent and intrinsic narrow therapeutic window for the molecule. The strategic conclusion was that even if regulatory approval could be achieved based on efficacy data in a niche population, the drug's difficult safety profile would severely limit its clinical utility, patient acceptance, and commercial viability. This holistic assessment, weighing not just statistical significance but the practical realities of clinical use, led to the decision to terminate the program and reallocate resources to other assets in the company's portfolio.

7.0 Concluding Analysis: The Legacy of Adavosertib and the Future of WEE1 Inhibition

The journey of adavosertib, from its promising preclinical rationale to its discontinuation after an extensive clinical program, offers a valuable case study in the complexities of oncology drug development. While it did not become a therapeutic product, its pioneering role as a first-in-class WEE1 inhibitor has left an indelible mark on the field, providing critical validation, key learnings, and a clear roadmap for its successors.

7.1 Summary of Adavosertib's Profile: A Pioneering but Flawed Agent

Adavosertib's profile is one of stark contrasts. Its primary strength was its identity as a potent, selective, first-in-class inhibitor of WEE1 kinase, underpinned by a robust scientific rationale. The principle of inducing synthetic lethality in cancers with G1 checkpoint defects (TP53 mutations) and high replication stress was successfully translated from the laboratory to the clinic. The drug produced reproducible signals of meaningful clinical activity, particularly in heavily pretreated, genomically unstable gynecological cancers where treatment options are limited.

However, this efficacy was inextricably linked to its fatal flaw: a narrow therapeutic index. The on-target mechanism of action, which was so effective against rapidly dividing cancer cells, was also responsible for significant toxicity in rapidly dividing normal tissues, namely the bone marrow and gastrointestinal tract. The resulting safety profile, characterized by high rates of myelosuppression and GI distress, was challenging to manage and consistently undermined the ability to deliver the drug at doses and schedules required for durable efficacy.

7.2 Key Learnings from the Adavosertib Program

The comprehensive clinical investigation of adavosertib has generated several crucial learnings that are now guiding the field of cell cycle checkpoint inhibition.

1. Target Validation: The adavosertib program unequivocally validated WEE1 as a legitimate and druggable therapeutic target in human cancer. The consistent efficacy signals across multiple tumor types confirmed that inhibiting this pathway can lead to objective tumor responses in appropriately selected patients.
2. Biomarker Identification and Refinement: The program provided the first large-scale clinical validation for the TP53-mutation-driven synthetic lethality hypothesis. More importantly, it expanded this concept by demonstrating the clinical relevance of biomarkers related to replication stress, such as CCNE1 amplification. The promising activity seen in CCNE1-amplified ovarian cancer has directly informed the development strategies of next-generation inhibitors, shifting the focus toward a more precise, biomarker-driven approach.
3. The Primacy of the Therapeutic Window: Adavosertib serves as a powerful reminder that clinical efficacy, even when statistically significant, is insufficient for a drug to be successful. A viable therapeutic requires a manageable safety profile that allows for sustained treatment at an effective dose. The inability of adavosertib to achieve this balance was its ultimate downfall and highlights the central challenge for this entire class of agents.

7.3 The Next Generation: The Evolving Landscape of WEE1 Inhibitors

The discontinuation of adavosertib created a significant opportunity for second-generation WEE1 inhibitors to enter the space, armed with the lessons learned from their predecessor.[2] The current landscape is led by several key molecules:

• Azenosertib (Zentalis Pharmaceuticals): Currently the most clinically advanced WEE1 inhibitor, azenosertib has become the new frontrunner. Data from its clinical program, including the DENALI trial in platinum-resistant ovarian cancer, have shown an ORR of approximately 31-35% in a biomarker-selected population (Cyclin E1 positive), an efficacy signal comparable to that of adavosertib.[38] The development of azenosertib has also been marked by safety concerns, including a partial clinical hold by the FDA due to sepsis-related deaths, underscoring that the class-specific toxicity profile remains a formidable challenge.[68] Its future success will hinge on whether its safety profile is demonstrably better than adavosertib's and whether the strict focus on the Cyclin E1 biomarker can sufficiently enrich for responders to create a favorable risk-benefit equation.[37]
• Debio 0123 (Debiopharm): This WEE1 inhibitor is in earlier stages of clinical development and is being investigated as both a monotherapy and in combination therapies for solid tumors, including glioblastoma and small cell lung cancer.[69] It is described as being highly selective and brain-penetrant, which could represent points of differentiation from adavosertib, particularly for treating central nervous system malignancies.[69]

7.4 Final Conclusion

Adavosertib was a pivotal molecule in the history of targeted cancer therapy. It successfully brought the concept of WEE1 inhibition from preclinical theory to clinical proof-of-concept, validating the target and demonstrating that abrogating the G2/M checkpoint is a viable anticancer strategy. While its own journey was ultimately halted by an insurmountable tolerability challenge, the wealth of data generated from its extensive clinical program has been invaluable. Adavosertib identified responsive patient populations, refined the biomarker strategy for the entire class, and starkly defined the safety hurdles that must be overcome. Its legacy is not one of failure, but of a critical and necessary first step that has paved the way and shaped the strategic direction for the more refined and potentially successful WEE1 inhibitors that now follow.

Works cited

1. Adavosertib - Wikipedia, accessed August 18, 2025, https://en.wikipedia.org/wiki/Adavosertib
2. AstraZeneca axes Moderna-partnered, phase 2 heart disease drug plus a Wee inhibitor, accessed August 18, 2025, https://www.fiercebiotech.com/biotech/astrazeneca-axes-moderna-partnered-phase-2-heart-disease-drug-amid-other-wee-pipeline
3. Adavosertib: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed August 18, 2025, https://go.drugbank.com/drugs/DB11740
4. MK-1775 | AZD-1775 | CAS#955365-80-7 | WEE1 inhibitor | MedKoo Biosciences, accessed August 18, 2025, https://www.medkoo.com/products/4700
5. Definition of adavosertib - NCI Drug Dictionary, accessed August 18, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/adavosertib
6. www.medchemexpress.com, accessed August 18, 2025, [https://www.medchemexpress.com/MK-1775.html#:~:text=Adavosertib%20(Synonyms%3A%20AZD1775%3B%20MK%2D1775)&text=Adavosertib%20(AZD%2D1775%3B%20MK,For%20research%20use%20only.](https://www.google.com/url?q=https://www.medchemexpress.com/MK-1775.html%23:~:text%3DAdavosertib%2520(Synonyms%253A%2520AZD1775%253B%2520MK%252D1775)%26text%3DAdavosertib%2520(AZD%252D1775%253B%2520MK,For%2520research%2520use%2520only.&sa=D&source=editors&ust=1755502325758292&usg=AOvVaw1aa-tbgfZ_WKYQ7tyQebmg)
7. Adavosertib Cancer Treatment Overview - Ontosight, accessed August 18, 2025, https://ontosight.ai/glossary/term/adavosertib-cancer-treatment-overview--67a0da066c3593987a502b24
8. Adavosertib Synonyms, accessed August 18, 2025, https://comptox.epa.gov/dashboard/chemical/synonyms/DTXSID30241868
9. MK-1775) | Wee1 inhibitor | CAS 955365-80-7 | Buy Adavosertib (AZD1775; MK1775) from Supplier InvivoChem, accessed August 18, 2025, https://www.invivochem.com/mk-1775.html
10. MK 1775 | C27H32N8O2 | CID 24856436 - PubChem, accessed August 18, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/mk-1775
11. adavosertib | C27H32N8O2 - ChemSpider, accessed August 18, 2025, https://www.chemspider.com/Chemical-Structure.24808590.html
12. Adavosertib #69589 - Cell Signaling Technology, accessed August 18, 2025, https://www.cellsignal.com/products/activators-inhibitors/adavosertib/69589
13. Compound: ADAVOSERTIB (CHEMBL1976040) - ChEMBL - EMBL-EBI, accessed August 18, 2025, https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1976040
14. Showing metabocard for Adavosertib (HMDB0254782) - Human Metabolome Database, accessed August 18, 2025, https://hmdb.ca/metabolites/HMDB0254782
15. Adavosertib | Checkpoint Control Kinase Inhibitors - R&D Systems, accessed August 18, 2025, https://www.rndsystems.com/products/adavosertib_7589
16. Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study - PMC, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7028795/
17. Indicators of Response to the Wee1 Inhibitor Adavosertib in Acute Myeloid Leukemia | Blood, accessed August 18, 2025, https://ashpublications.org/blood/article/142/Supplement%201/5007/504260/Indicators-of-Response-to-the-Wee1-Inhibitor
18. Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations - Frontiers, accessed August 18, 2025, https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2021.737951/full
19. What WEE1 inhibitors are in clinical trials currently? - Patsnap Synapse, accessed August 18, 2025, https://synapse.patsnap.com/article/what-wee1-inhibitors-are-in-clinical-trials-currently
20. Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring - ASCO Publications, accessed August 18, 2025, https://ascopubs.org/doi/10.1200/JCO.21.01435
21. A phase Ib study of adavosertib, a selective Wee1 inhibitor, in patients with locally advanced or metastatic solid tumors, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10289903/
22. Adavosertib and Beyond: Biomarkers, Drug Combination and Toxicity of WEE1 Inhibitors, accessed August 18, 2025, https://www.researchgate.net/publication/376548233_Adavosertib_and_Beyond_Biomarkers_Drug_Combination_and_Toxicity_of_WEE1_Inhibitors?_tp=eyJjb250ZXh0Ijp7InBhZ2UiOiJzY2llbnRpZmljQ29udHJpYnV0aW9ucyIsInByZXZpb3VzUGFnZSI6bnVsbCwic3ViUGFnZSI6bnVsbH19
23. Adavosertib | Checkpoint Control Kinases - Tocris Bioscience, accessed August 18, 2025, https://www.tocris.com/products/adavosertib_7589
24. Adavosertib (Standard) (AZD1775 (Standard)) | Wee1 Inhibitor | MedChemExpress, accessed August 18, 2025, https://www.medchemexpress.com/adavosertib-standard.html
25. Effects of Wee1 inhibitor adavosertib on patient-derived high-grade serous ovarian cancer cells are multiple and independent of homologous recombination status, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9445195/
26. Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer | Journal of Clinical Oncology - ASCO Publications, accessed August 18, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.19.00730
27. (PDF) Effect of food on the pharmacokinetics of the WEE1 inhibitor ..., accessed August 18, 2025, https://www.researchgate.net/publication/342252179_Effect_of_food_on_the_pharmacokinetics_of_the_WEE1_inhibitor_adavosertib_AZD1775_in_patients_with_advanced_solid_tumors
28. The WEE1 Inhibitor Adavosertib Displays Promising Clinical Activity in Uterine Serous Cancer - American Health & Drug Benefits, accessed August 18, 2025, https://www.ahdbonline.com/issues/2020/august-2020-vol-13-special-issue/the-wee1-inhibitor-adavosertib-displays-promising-clinical-activity-in-uterine-serous-cancer
29. Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with m, accessed August 18, 2025, https://ccsp.hms.harvard.edu/wp-content/uploads/2021/10/Keenan-2021.pdf
30. Adavosertib Completed Phase 2 Trials for Ovarian Cancer Treatment | DrugBank Online, accessed August 18, 2025, https://go.drugbank.com/drugs/DB11740/clinical_trials?conditions=DBCOND0028213&phase=2&purpose=treatment&status=completed
31. Adavosertib Completed Phase 1 Trials for Solid Tumors Treatment | DrugBank Online, accessed August 18, 2025, https://go.drugbank.com/drugs/DB11740/clinical_trials?conditions=DBCOND0029860&phase=1&purpose=treatment&status=completed
32. Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial - PubMed, accessed August 18, 2025, https://pubmed.ncbi.nlm.nih.gov/39487373/
33. ADAGIO: A Phase IIb, Open-Label, Single-Arm, Multicenter Study Assessing the Efficacy and Safety of Adavosertib (AZD1775) as Treatment for Recurrent or Persistent Uterine Serous Carcinoma - ASCO Publications, accessed August 18, 2025, https://ascopubs.org/doi/10.1200/JCO-24-01606
34. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring - DigitalCommons@TMC, accessed August 18, 2025, https://digitalcommons.library.tmc.edu/cgi/viewcontent.cgi?article=2266&context=uthgsbs_docs
35. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification | Journal of Clinical Oncology - ASCO Publications, accessed August 18, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.22.00830
36. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification - PubMed, accessed August 18, 2025, https://pubmed.ncbi.nlm.nih.gov/36469840/
37. Zentalis doubles down on Wee1 | ApexOnco - Clinical Trials news ..., accessed August 18, 2025, https://www.oncologypipeline.com/apexonco/zentalis-doubles-down-wee1
38. Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer, accessed August 18, 2025, https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-presents-updated-clinical-data-society/
39. Azenosertib Shows Promising Efficacy in Platinum-Resistant Ovarian Cancer, accessed August 18, 2025, https://www.targetedonc.com/view/azenosertib-shows-promising-efficacy-in-platinum-resistant-ovarian-cancer
40. Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies, accessed August 18, 2025, https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-announces-azenosertib-fast-track/
41. Pharmacokinetics: Definition & Use in Drug Development - Allucent, accessed August 18, 2025, https://www.allucent.com/resources/blog/what-pharmacokinetics-and-adme
42. What is ADME and how does it fit into drug development? - BioIVT, accessed August 18, 2025, https://bioivt.com/blogs/what-is-adme-and-how-does-it-fit-into-drug-development
43. A Phase 2 Study of the Wee1 inhibitor Adavosertib (AZD1775) in women with recurrent or persistent uterine serous carcinoma or uterine carcinosarcoma | Dana-Farber Cancer Institute, accessed August 18, 2025, https://www.dana-farber.org/clinical-trials/18-316
44. Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | ClinicalTrials.gov, accessed August 18, 2025, https://clinicaltrials.gov/study/NCT02272790
45. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170) - AACR Journals, accessed August 18, 2025, https://aacrjournals.org/cancerrescommun/article/4/7/1793/746640/A-Phase-II-Trial-of-the-WEE1-Inhibitor-Adavosertib
46. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma, accessed August 18, 2025, https://pubmed.ncbi.nlm.nih.gov/33705205/
47. AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma | ClinicalTrials.gov, accessed August 18, 2025, https://www.clinicaltrials.gov/study/NCT03668340
48. Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma, accessed August 18, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.20.03167
49. A Study of Adavosertib as Treatment for Uterine Serous Carcinoma - NCI, accessed August 18, 2025, https://www.cancer.gov/clinicaltrials/NCI-2020-11488
50. Adavosertib in Recurrent or Persistent Uterine Serous Carcinoma - The ASCO Post, accessed August 18, 2025, https://ascopost.com/news/may-2025/adavosertib-in-recurrent-or-persistent-uterine-serous-carcinoma/
51. Poor Tolerability Appears to Hinder Benefit of Adavosertib in Uterine Serous Carcinoma, accessed August 18, 2025, https://ascopost.com/issues/may-25-2023/poor-tolerability-appears-to-hinder-benefit-of-adavosertib-in-uterine-serous-carcinoma/
52. Adavosertib Active in Uterine Cancer, But Tolerability Limits Use - Targeted Oncology, accessed August 18, 2025, https://www.targetedonc.com/view/adavosertib-active-in-uterine-cancer-but-tolerability-limits-use
53. EFFORT Study of Adavosertib with or without Olaparib in Women ..., accessed August 18, 2025, https://jons-online.com/articles/effort-study-of-adavosertib-with-or-without-olaparib-in-women-with-parp-resistant-ovarian-cancer
54. Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring - ASCO Publications, accessed August 18, 2025, https://ascopubs.org/doi/abs/10.1200/JCO.21.01435
55. Clinical efficacy and molecular response correlates of the WEE1 inhibitor adavosertib combined with cisplatin in patients with metastatic triple-negative breast cancer (mTNBC), accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7887044/
56. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors - PMC - PubMed Central, accessed August 18, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10345044/
57. Adavosertib Active Not Recruiting Phase 2 Trials for Metastatic Renal Cell Carcinoma ( mRCC) / Clear Cell Renal Cell Carcinoma / metastatic Malignant Solid Neoplasms Treatment - DrugBank, accessed August 18, 2025, https://go.drugbank.com/drugs/DB11740/clinical_trials?conditions=DBCOND0029155%2CDBCOND0153815%2CDBCOND0123126&phase=2&purpose=treatment&status=active_not_recruiting
58. (PDF) A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors - ResearchGate, accessed August 18, 2025, https://www.researchgate.net/publication/371348355_A_Phase_Ib_Study_Assessing_the_Safety_Tolerability_and_Efficacy_of_the_First-in-Class_Wee1_Inhibitor_Adavosertib_AZD1775_as_Monotherapy_in_Patients_with_Advanced_Solid_Tumors
59. Protein kinase inhibitor - Wikipedia, accessed August 18, 2025, https://en.wikipedia.org/wiki/Protein_kinase_inhibitor
60. FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer, accessed August 18, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low
61. Oncology (Cancer)/Hematologic Malignancies Approval Notifications - FDA, accessed August 18, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications
62. European Medicines Agency (EMA), accessed August 18, 2025, https://www.ema.europa.eu/en/medicines
63. New Treatment Options In Oncology: FDA And EMA Drug Approvals In Q4 2022, accessed August 18, 2025, https://www.aptitudehealth.com/oncology-news/fda-ema-drug-approvals-q4-2022/
64. Adavosertib - AstraZeneca - AdisInsight - Springer, accessed August 18, 2025, https://adisinsight.springer.com/drugs/800028808
65. European Medicines Agency decision P/0512/2021 of 3 December 2021 on the granting of a product specific waiver for adavosertib,, accessed August 18, 2025, https://www.ema.europa.eu/en/documents/pip-decision/p-0512-2021-ema-decision-3-december-2021-granting-product-specific-waiver-adavosertib-emea-003069-pip01-21_en.pdf
66. EMEA-003069-PIP01-21 - paediatric investigation plan - EMA - European Union, accessed August 18, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-003069-pip01-21
67. Zentalis Pharmaceuticals Updates Azenosertib Clinical Data in Platinum-Resistant Ovarian Cancer, On Track for DENALI Part 2 Initiation in 2025 | Nasdaq, accessed August 18, 2025, https://www.nasdaq.com/articles/zentalis-pharmaceuticals-updates-azenosertib-clinical-data-platinum-resistant-ovarian
68. FDA places partial clinical hold on Zentalis' trials of azenosertib for cancer, accessed August 18, 2025, https://www.clinicaltrialsarena.com/news/fda-hold-zentalis-trials/
69. Debio 0123 - Debiopharm, accessed August 18, 2025, https://www.debiopharm.com/pipeline/debio-0123/
70. Debiopharm Launches Phase 1 Research in Small Cell Lung Cancer with WEE1 inhibitor Debio 0123 to Outsmart DDR, accessed August 18, 2025, https://www.debiopharm.com/drug-development/press-releases/debiopharm-launches-phase-1-research-in-small-cell-lung-cancer-with-wee1-inhibitor-debio-0123-to-outsmart-ddr/
71. Debio 0123, a selective, brain penetrant WEE1 inhibitor in clinical development for patients with solid tumors - Debiopharm, accessed August 18, 2025, https://www.debiopharm.com/drug-development/publications/debio-0123-a-selective-brain-penetrant-wee1-inhibitor-in-clinical-development-for-patients-with-solid-tumors/